EUVIMEDEUVIMED entdecken
Crossref

Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC

Alessandro Leonetti, Veronica Cervati, Roberta Minari, Maura Scarlattei, Michela Verzè, Marianna Peroni, Monica Pluchino, Francesco Bonatti, Fabiana Perrone, Giulia Mazzaschi, Agnese Cosenza, Letizia Gnetti und 3 weitere

Clinical Lung Cancer · 2024

DOI: 10.1016/j.cllc.2024.07.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Alessandro Leonetti und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Unit, University Hospital of Parma, Parma, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Acrylamides, Aniline Compounds, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Airc Italian Foundation for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Despite the outstanding results achieved by osimertinib for the treatment of advanced EGFR-mutated NSCLC, the development of resistance is almost inevitable. While molecular mechanism responsible for osimertinib resistance are being mostly revealed, the definition of predictive biomarkers is crucial in order to identify patients at higher risk of progression and optimize treatment strategy. MATERIALS AND METHODS: This is a prospective single-center study aimed to assess the potential role of liquid biopsy and 18F-FDG PET/CT derived metabolic parameters as noninvasive predictive biomarkers of osimertinib outcomes in advanced EGFR-mutated NSCLC patients. Patients underwent blood samples for ctDNA analysis at baseline, after 15 days and 1 month (t1) of osimertinib. 18F-FDG PET/CT was performed at baseline and after 1 month of osimertinib. RESULTS: Seventy-two advanced EGFR-mutated NSCLC patients treated with osimertinib in first (n = 63) and in second-line (n = 9) were prospectively enrolled. Baseline positive shedding status was significantly associated with a shorter progression-free survival (PFS) (9.5 vs. 29.2 months, P = .031). Early metabolic response (MR) led to improved PFS (16.8 vs. 5.5 months, P = .038) and OS (35.2 vs. 15.3 months, P = .047). Early MR was significantly correlated with subsequent radiologic response (P = .010). All 18F-FDG PET/CT baseline parameters were significantly related to baseline EGFR activating mutation allele frequency. Both clearance and no detection of EGFR at t1 were significantly associated with MR (P = .001 and P = .004, respectively). CONCLUSION: Molecular and 18F-FDG PET/CT derived metabolic parameters might represent a useful tool to predict osimertinib outcome in advanced EGFR-mutated NSCLC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAcrylamidesAniline CompoundsLung NeoplasmsErbB ReceptorsPositron Emission Tomography Computed TomographyFluorodeoxyglucose F18MutationHumansMaleFemaleMiddle AgedAgedProspective StudiesLiquid BiopsyAdultAged, 80 and overPrognosisRadiopharmaceuticalsAntineoplastic AgentsIndolesPyrimidines

Stichwörter der Autor:innen

Circulating tumor DNAEGFR-tyrosine kinase inhibitorsMetabolic responseStandard uptake valueTotal lesion glycolysis

Substanzen

osimertinibAcrylamidesAniline CompoundsErbB ReceptorsFluorodeoxyglucose F18EGFR protein, humanRadiopharmaceuticalsAntineoplastic AgentsIndolesPyrimidines

Autor:innen und Institutionen

  • Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
  • Nuclear Medicine Unit, University Hospital of Parma, Parma, Italy.
  • Medical Oncology Unit, University Hospital of Parma, Parma, Italy. Electronic address: rominari@ao.pr.it.
  • Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Medical Oncology Unit, University Hospital of Parma, Parma, Italy; Department of Medicine and Surgery, University of Parma, Parma, Italy.
  • Pathology Unit, Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy.

Förderung

  • Associazione Italiana per la Ricerca sul Cancro
  • Airc Italian Foundation for Cancer Research

Zitieren

APA

Leonetti, A., Cervati, V., Minari, R., Scarlattei, M., Verzè, M., Peroni, M., Pluchino, M., Bonatti, F., Perrone, F., Mazzaschi, G., Cosenza, A., Gnetti, L., Bordi, P., Ruffini, L., & Tiseo, M. (2024). Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.07.016

Vancouver

Leonetti A, Cervati V, Minari R, Scarlattei M, Verzè M, Peroni M, et al. Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC. Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2024.07.016

BibTeX
@article{Leonetti2024,
  author = {Leonetti, Alessandro and Cervati, Veronica and Minari, Roberta and Scarlattei, Maura and Verzè, Michela and Peroni, Marianna and Pluchino, Monica and Bonatti, Francesco and Perrone, Fabiana and Mazzaschi, Giulia and Cosenza, Agnese and Gnetti, Letizia and Bordi, Paola and Ruffini, Livia and Tiseo, Marcello},
  title = {Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC},
  journal = {Clinical Lung Cancer},
  year = {2024},
  doi = {10.1016/j.cllc.2024.07.016}
}
Kostenlos starten →